hotspot -WSS

hotspot

author：knowledge 2025-10-02 09:47:19 - browse：255

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： AstraZeneca stays mum on Medicare drug pricing negotiations

hotspot

WSS

Top private equity targets in 2023: cardiology, clinical trials, lasers

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Neuroscience’s long legacy of racism

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Orchard's therapy for neuron disease in children wins FDA approval

Plastic surgeons increase patient psychiatric screenings

hotspot

hotspot

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

5 to watch: Tech startups trying to solve health care's staffing crisis

State Dept. review finds Biden bears some blame for Afghanistan failures

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

State Dept. review finds Biden bears some blame for Afghanistan failures

AstraZeneca stays mum on Medicare drug pricing negotiations

In Memoriam: Notable people who died in 2023

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Duchenne breakthrough therapy leaves behind pioneering families

Updated Covid vaccine has 54% effectiveness, new study suggests

Wikipedia

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Positive childhood experiences can help future health

Devoted Health’s losses in Medicare Advantage persist

Problems with a popular proposal to regulate AI in health care

Why CTE doesn’t keep Americans from enjoying the Super Bowl

entertainment

entertainment

hotspot

leisure time